Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a 5-Day pill course prevent long COVID? major trial underway

NCT ID NCT05852873

First seen Nov 21, 2025 · Last updated Jun 22, 2026 · Updated 24 times

Summary

This study tests whether taking Paxlovid (an antiviral pill) during the first 5 days of a COVID-19 infection can prevent long-COVID symptoms like fatigue, shortness of breath, and memory problems. About 2000 adults aged 18-64 in Norway will receive either Paxlovid or a placebo, plus standard care. Researchers will check for long-COVID symptoms 3 months later.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Haukeland University Hospital

    Bergen, Vestland, 5021, Norway

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Paxlovid (nirmatrelvir/ritonavir)

What this could lead to

If it works, this could show that taking Paxlovid early during a COVID-19 infection reduces the chance of developing long-COVID symptoms like fatigue, breathlessness, and brain fog.

What could go wrong

This is a large phase 3 trial, but long-COVID is complex and may not be prevented by a short antiviral course. The results may not apply to everyone, and Paxlovid can have side effects or interact with other medications.

Conditions

The condition(s) this trial relates to.

COVID-19 long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.